| Jul 29 |
Neurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%
|
| Jul 29 |
Anavex seek EMA approval despite shaky pivotal Alzheimer’s trial data
|
| Jul 29 |
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
|
| Jul 29 |
Anavex's blarcamesine slowed cognitive decline in phase 2/3 early Alzheimer's trial
|
| Jul 28 |
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
|
| Jul 16 |
Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
| Jul 9 |
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
|
| Jul 9 |
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
|
| Jul 1 |
Institutions own 38% of Anavex Life Sciences Corp. (NASDAQ:AVXL) shares but individual investors control 59% of the company
|
| Jun 20 |
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
